Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651663 | 1.00 | MAPT (0.53) | MAPTALDH1A1GAAKDM4EHTT | |
| SCHEMBL15652154 | 1.00 | MAPT (0.53) | MAPTALDH1A1GAAKDM4EHTT | |
| SCHEMBL15650766 | 0.89 | AR (0.49) | MAPTALDH1A1GAAKDM4EHTT | |
| SCHEMBL6253761 | 0.89 | MAPT (0.62) | MAPTALDH1A1GAAKDM4EHTT | |
| SCHEMBL853367 | 0.89 | AR (0.49) | MAPTALDH1A1GAAKDM4EHTT | |
| SCHEMBL33623 | 0.89 | AR (0.49) | MAPTALDH1A1GAAKDM4EHTT | |
| Hydrochloric Acid SCHEMBL5406643 | 0.87 | MAPT (0.50) | MAPTALDH1A1GAAKDM4EHTT | |
| Hydrochloric Acid SCHEMBL5393462 | 0.87 | MAPT (0.50) | MAPTALDH1A1GAAKDM4EHTT | |
| Hydrochloric Acid SCHEMBL1154260 | 0.87 | MAPT (0.50) | MAPTALDH1A1GAAKDM4EHTT | |
| SCHEMBL6219283 | 0.86 | MAPT (0.58) | MAPTALDH1A1GAAKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022216097-A1 | NOVEL LRRK2 INHIBITOR | 주식회사 스탠다임 | 2022-10-13 | — | — | WO | disclosed |
| WO-2022216098-A1 | NOVEL LRRK2 INHIBITOR | 주식회사 스탠다임 | 2022-10-13 | — | — | WO | disclosed |
| WO-2022203466-A1 | NOVEL PHENYLAMINOPYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY AGAINST LRRK2 AND USE THEREOF | 주식회사 스탠다임 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022203466-A1 | NOVEL PHENYLAMINOPYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY AGAINST LRRK2 AND USE THEREOF | 주식회사 스탠다임 | 2022-09-29 | — | — | WO | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| CN-1138778-C | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidine sas inhibitors of cellular proliferation | ��ʲ | 2004-02-18 | — | — | CN | disclosed |
| CN-1433417-A | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | WARNER LAMBERT CO (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| CN-1302301-A | bicyclic pyrimidines and bicyclic 3, 4-dihydropyrimidine compounds useful as inhibitors of cell proliferation | WARNER LAMBERT CO (US) | 2001-07-04 | — | — | CN | disclosed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | MAPT 2232/4885ALDH1A1 4260/4885GAA 3183/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885ALDH1A1 4333/4885GAA 742/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | MAPT 2232/4885ALDH1A1 4260/4885GAA 3183/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885ALDH1A1 4184/4885GAA 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.